AMBASSADOR trial finds adjuvant pembrolizumab extends disease-free survival in high-risk bladder cancer — not yet FDA-approved for this use

Research type: Later-stage studies in peopleRegulatory status: InvestigationalGuideline status: Not addressed

In plain English

The 30-second version

What happened?

In the randomized, phase 3 AMBASSADOR trial, adjuvant pembrolizumab after radical surgery significantly extended disease-free survival compared with observation alone in patients with high-risk muscle-invasive or locally advanced urothelial carcinoma. This is a real, positive trial result — but pembrolizumab has NOT been granted FDA approval for this specific adjuvant indication. A different, related PD-1 inhibitor, nivolumab, already holds that FDA approval (since 2021) for a similar adjuvant urothelial-carcinoma setting, and AMBASSADOR's own enrollment was closed early because of that competing approval.

Why does it matter?

A second PD-1 inhibitor demonstrating a real disease-free-survival benefit in this adjuvant bladder-cancer setting strengthens the overall evidence base for immunotherapy after bladder-removal surgery, even though this specific drug/indication pairing has not itself been approved.

What does this not prove?

This must never be described or badged as an FDA-approved use of pembrolizumab — readers should not confuse this drug's AMBASSADOR trial result with nivolumab's separate, already-approved adjuvant indication. Overall survival, the trial's co-primary endpoint, was not yet statistically significant at the reported follow-up and remains an immature endpoint — this record makes no overall-survival claim.

Keep reading for evidence stage, limitations, study details, and sources.

Study details are available in the source report.

Population / Applicability

Studied in: Adults with high-risk muscle-invasive or locally advanced urothelial (bladder) carcinoma, following radical surgical removal of the bladder (radical cystectomy or nephroureterectomy), randomized to adjuvant pembrolizumab or observation alone. (Adults)

Do not present this as an available, FDA-approved treatment option — as of this review, patients seeking an approved adjuvant PD-1 inhibitor after bladder-removal surgery would be considering nivolumab, a different drug, not pembrolizumab in this specific setting. Overall-survival data remain immature and should be re-checked before this record is revised.

Full evidence details
Study design
Randomized controlled trial
Sample size
702

Funding & Conflicts

Sponsor: National Cancer Institute (NCI), led by the Alliance for Clinical Trials in Oncology, with Merck (pembrolizumab's manufacturer) participating via a Cooperative Research and Development Agreement (CRADA) — not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

Country or region not specified

Status
Investigational
Last verified
2026-08-13

Cancer-type scope for this record is not yet recorded.

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Additional context

Last reviewed

Related discoveries

AMBASSADOR trial finds adjuvant pembrolizumab extends disease-free survival in high-risk bladder cancer — not yet FDA-approved for this use

https://cancerdiscoveries.com/discoveries/ambassador-trial-finds-adjuvant-pembrolizumab-extends-disease-free-survival-in-high-risk-bladder-cancer-not-yet-fda-approved-for-this-use/

Research type: Later-stage studies in people

What This Means

In the randomized, phase 3 AMBASSADOR trial, adjuvant pembrolizumab after radical surgery significantly extended disease-free survival compared with observation alone in patients with high-risk muscle-invasive or locally advanced urothelial carcinoma. This is a real, positive trial result — but pembrolizumab has NOT been granted FDA approval for this specific adjuvant indication. A different, related PD-1 inhibitor, nivolumab, already holds that FDA approval (since 2021) for a similar adjuvant urothelial-carcinoma setting, and AMBASSADOR's own enrollment was closed early because of that competing approval.

What This Doesn't Mean

This must never be described or badged as an FDA-approved use of pembrolizumab — readers should not confuse this drug's AMBASSADOR trial result with nivolumab's separate, already-approved adjuvant indication. Overall survival, the trial's co-primary endpoint, was not yet statistically significant at the reported follow-up and remains an immature endpoint — this record makes no overall-survival claim.

Why It Matters

A second PD-1 inhibitor demonstrating a real disease-free-survival benefit in this adjuvant bladder-cancer setting strengthens the overall evidence base for immunotherapy after bladder-removal surgery, even though this specific drug/indication pairing has not itself been approved.

Primary sources

  • AMBASSADOR/A031501 trial primary results: adjuvant pembrolizumab in muscle-invasive urothelial carcinoma (NEJM) — https://doi.org/10.1056/NEJMoa2401726 (DOI 10.1056/NEJMoa2401726, PMID 39282902)

Date verified: 2026-08-13

Correction status: No correction or retraction